Fairvalue-Calculator Fairvalue-Calculator
EN DE

Together Pharma Ltd (TGTR) Fair Value & Analysis

Healthcare · Il · Market cap 40.6M ILA

Price2.25 ILA
Fair Value2.42 ILA
Upside+7.7%
Quality93/100
Evidence: High Range 2.13 ILA – 3.03 ILA

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Together Pharma Ltd (TGTR) currently trades at 2.25 ILA, while our model-based Fair Value estimate is 2.42 ILA — implying the stock looks roughly 7.7% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Together Pharma Ltd, through its subsidiaries, engages in the cultivation, propagation, import, export, production, storage and distribution of medical cannabis products in Israel. It offers cannabis oils and inflorescences. The company was incorporated in 1991 and is based in Ashkelon, Israel.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Together Pharma Ltd (TGTR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 2.42 ILA versus a price of 2.25 ILA — about +8% (undervalued). Model-based estimate, not financial advice.
What is the fair value of TGTR?
Our 21-model fair value for Together Pharma Ltd is 2.42 ILA (as of Jun 25, 2026), built from audited fundamentals. The current price is 2.25 ILA.
What is the quality score of TGTR?
Together Pharma Ltd has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.